Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Usefulness of resistant gene markers for predicting treatment outcome on second-line anti-tuberculosis drugs.

Journal of applied microbiology - 1 Dec 2010

Leung K L, Yip C W, Yeung Y L, Wong K L, Chan W Y, Chan M Y, Kam K M

Abstract excerpt

AIM: Mutations in rrs [nucleotide (nt) 1401], gyrA gene (codons 90, 91 or 94), tlyA, ethA and thyA genes of Mycobacterium tuberculosis (MTB) were evaluated for their usefulness in predicting treatment outcome of kanamycin (KM), capreomycin (CPM), ofloxacin (OFX), ethionamide (ETH) and para-aminosalicylic acid (PAS). METHODS AND RESULTS: DNA sequence analyses of these genes were performed against 188 MTB isolates...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Drug Resistance, Bacterial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, Bacterial

Share to Microbial Sensitivity Tests

Share to Mycobacterium tuberculosis

Share to Predictive Value of Tests

Share to Sensitivity and Specificity

Share to Tuberculosis

Source

Identifiers

PMID: 20854453
DOI: 10.1111/j.1365-2672.2010.04840.x

Genes

CPM
IMPACT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Usefulness of resistant gene markers for predicting treatment outcome on second-line anti-tuberculosis drugs.PMID 20854453Read ↗

Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates.Semantic proximity Read ↗

Investigation of Gene Regions Responsible for Drug Resistance in Clinical Isolates of Mycobacterium tuberculosis Complex Resistant to at Least Two First-Line Anti-Tuberculosis Drugs.Semantic proximity Read ↗

Frequency of first and second-line drug resistance-associated mutations among resistant Mycobacterium tuberculosis clinical isolates from São Paulo, Brazil.Semantic proximity Read ↗

Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment.Semantic proximity Read ↗

Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations.Semantic proximity Read ↗

Molecular Characterization of Resistance to Second-Line Anti-Mycobacterial Drugs among Clinical Isolates of Multidrug-Resistant Mycobacterium tuberculosis.Semantic proximity Read ↗

Specific<i>gyrA</i>gene mutations predict poor treatment outcome in MDR-TBSemantic proximity Read ↗

Second Line Injectable Drug Resistance and Associated Genetic Mutations in Newly Diagnosed Cases of Multidrug-Resistant Tuberculosis.Semantic proximity Read ↗

Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review.Semantic proximity Read ↗

Utility of Phenotypic and Genotypic Testing in the Study of Mycobacterium tuberculosis Resistance to First-Line Anti-Tuberculosis drugs.Semantic proximity Read ↗

Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre studySemantic proximity Read ↗

Clinical implications of high-risk mutations in drug resistant tuberculosis (DR-TB): An observational cohort study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.